Your GLP-1 was denied. Which kind of no was it?

Three different things get called a denial and only two are worth appealing. If your plan excludes weight-loss drugs as a category, the refusal is not about you and no amount of clinical documentation moves it. If it is step therapy or unmet criteria, both are answerable, and the answer is usually documentation rather than argument. Here is how to tell which one you got, and what each needs.

Julian CaraulaniFounder, PriceTracker GLP-1Last checked Aug 28We track prices. Clinical facts on this site are quoted from the drug's label, the FDA or the published trial, with the source and the date beside each one. We do not write medical guidance and we do not tell anyone what to take.

7 min read · published Aug 28

The short version

  • 1A benefit exclusion is not a clinical decision. Chart notes cannot appeal it; only a plan change or an exception can.
  • 2Step therapy is a sequence, not a refusal, and documented failure or intolerance is the way through.
  • 3Unmet criteria is the most winnable, and usually fails on missing documentation rather than missing facts.
  • 4Formularies reverse: Caremark dropped Zepbound in 2025 and brings it back on 1 October 2026.

A denial letter rarely says which kind of no it is, and the three kinds need completely different responses. Sorting yours correctly is worth more than any template letter.

Kind one: your plan excludes the category

This is the most common and the most misunderstood. Cigna states it in its own policy:1

Weight loss medications are specifically excluded under many benefit plans

Cigna

An exclusion is a decision your employer made when they bought the plan. It is not a judgement about your BMI, your comorbidities or your effort, which means clinical evidence cannot move it. People spend weeks assembling chart notes for a reviewer who is not weighing the clinical case at all.

Worth knowing

How to recognise it: the wording refers to your benefit, your plan or an exclusion, rather than to criteria, thresholds or medical necessity. If in doubt, ask member services one question: is this drug excluded from my plan's benefit, or did it fail the prior-authorisation criteria? They are different answers and they lead in opposite directions.

What can work instead. Ask HR whether the employer plans to add the weight-loss benefit at renewal, since this is decided annually and plenty of employers are revisiting it. Ask whether a different indication opens a door: UnitedHealthcare's own policy points to separate criteria for Zepbound in obstructive sleep apnea on plans that do not cover weight-loss drugs.4 And price the cash route, because for an excluded plan that is the realistic comparison.

Kind two: step therapy

This one reads like a refusal and is really a sequence. Caremark's own member communication is the clearest example anyone has published:2

we've made the decision to remove Zepbound from coverage. Wegovy and Saxenda remain preferred. … All members, regardless of indication, will need to have tried and failed Wegovy before they can access tirzepatide.

CVS Caremark

Note what that actually says. Not never. It says try the preferred drug first, and if it fails, the other one becomes available. So the route through is a documented trial: what you took, for how long, at what dose, and what happened, whether that was inadequate response, intolerance or a contraindication.

The instrument is usually called a formulary exception rather than an appeal, and your prescriber files it. The distinction matters when you phone up, because asking for the wrong process gets you routed to the wrong queue.

Kind three: criteria not met

The most winnable of the three, and the one that most often fails on paperwork rather than on facts.

Reviewers check for documented things: a baseline weight and BMI recorded before treatment, a weight-related comorbidity named in the chart, and a period of lifestyle and dietary change with dates on it. A year of genuine effort that nobody wrote down does not exist for this purpose.

  • If the BMI was wrong or stale, a current recorded measurement fixes it.
  • If a comorbidity exists but was not stated, it needs to be in the notes, not just true.
  • If the lifestyle requirement was the gap, ask your prescriber to document what you are doing from today. Three to six months is the usual bar, so starting the clock now is worth more than arguing about the past.

Ask for the criteria document. Your plan has one, it is written down, and it lists exactly what the reviewer looks for. Appealing without reading it is guessing.

Formularies do reverse

Worth knowing before you conclude the door is permanently shut. Caremark removed Zepbound from its commercial formularies in July 2025, and then:3

CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026

CVS Health
In plain English

Same drug, same benefit manager, opposite answers fourteen months apart. If you were denied in that window, the denial has an expiry date and is worth re-running rather than re-appealing. It is also a reason to re-check an old no generally, rather than treating it as settled.

The order to work in

  • Establish which kind of no you got, in one call to member services. Everything else follows from it.
  • Exclusion: stop appealing, ask HR about renewal, ask about alternative indications, and price the cash route.
  • Step therapy: document the trial of the preferred drug and have your prescriber file a formulary exception.
  • Criteria: get the criteria document, find the specific gap, and fix it with documentation rather than argument.
  • Either way, note the date. Formularies change every year and some change mid-year.

Our coverage tracker carries the verified position for seven insurers across four brands, quoted from their own material with the date we read it, and the four gates explains the process from the top.

While you sort it out

The cash market is not a consolation prize, and for an excluded plan it is often the only honest comparison:

Sources4
  1. Cigna, weight-loss GLP-1 coverage policy read Aug 20“Weight loss medications are specifically excluded under many benefit plans” ↩
  2. CVS Caremark, formulary change communicated to plan members read Aug 20“we've made the decision to remove Zepbound from coverage. Wegovy and Saxenda remain preferred. … All members, regardless of indication, will need to have tried and failed Wegovy before they can access tirzepatide.” ↩
  3. CVS Health, Zepbound returning to commercial formularies read Aug 20“CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026” ↩
  4. UnitedHealthcare, weight-loss prior authorisation programme read Aug 20“Zepbound is being requested for moderate to severe obstructive sleep apnea … Refer to Nonformulary Zepbound criteria for plans that do not cover weight loss medications.” ↩

Common questions

What do I do if my insurance denies Wegovy?

Find out which kind of denial it is before you write anything. If weight-loss drugs are excluded from your plan's benefit, no clinical documentation will change it and an appeal is the wrong tool. If it is step therapy or unmet criteria, both are answerable, usually with documentation rather than argument. One call to member services asking whether the drug is excluded or failed the criteria tells you which.

Can I appeal a weight-loss drug exclusion?

Generally no, because an exclusion is a plan-design decision your employer made rather than a clinical decision about you, so there is no medical judgement to overturn. What can work is asking HR whether the benefit will be added at renewal, asking whether a different indication such as obstructive sleep apnea has its own criteria, or moving to the cash market.

What is a formulary exception?

A request to cover a drug that is not preferred on your plan's formulary, usually filed by your prescriber and usually supported by evidence that the preferred alternative failed, was not tolerated, or is contraindicated. It is a different process from an appeal, and asking for the right one gets you to the right queue faster.

Do I have to try Wegovy before Zepbound?

On some plans yes. CVS Caremark told members that all of them, regardless of indication, would need to have tried and failed Wegovy before accessing tirzepatide. That is step therapy rather than a refusal, so a documented trial is the route through. Caremark is also adding Zepbound back as a preferred option on 1 October 2026, which changes the answer again.

Does a denial ever expire?

Effectively yes, because formularies are revised at least annually and sometimes mid-year. Caremark removed Zepbound from its commercial formularies in July 2025 and is returning it as a preferred option on 1 October 2026, so a denial from that window is worth re-running rather than re-appealing.

Is an appeal letter template worth using?

Less than people expect. Reviewers check specific documented items against a written criteria document your plan will give you on request: baseline weight and BMI, a named weight-related condition, and a dated period of lifestyle change. Supplying those beats persuasive prose, and if the denial was a benefit exclusion, no letter of any quality will help.

Read next

Buying safelyHow to get a GLP-1 covered by insurance, in the order it actually works8 min · checked Aug 28What it costsGLP-1s without insurance: what each route actually costs7 min · checked Aug 28What it costsGLP-1 coupons and copay cards: the $25 headline and the $100 cap6 min · checked Aug 27